Xpovio (selinexor) — United Healthcare
HHV8-positive diffuse large B-cell lymphoma
Initial criteria
- Diagnosis of one of: relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including histologic transformation of indolent lymphomas to DLBCL; relapsed or refractory HIV-related DLBCL, primary effusion lymphoma, or HHV8-positive DLBCL; relapsed or refractory monomorphic B-cell type post-transplant lymphoproliferative disorder AND Patient has received at least 2 lines of systemic therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Xpovio therapy
Approval duration
12 months